ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 254 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $778 | -21.8% | 28,950 | +3.7% | 0.01% | -28.6% |
Q2 2023 | $995 | +26.3% | 27,909 | -10.0% | 0.01% | +40.0% |
Q1 2023 | $788 | -35.9% | 31,023 | +2.3% | 0.01% | -44.4% |
Q4 2022 | $1,230 | -99.9% | 30,326 | -7.7% | 0.01% | +12.5% |
Q3 2022 | $1,086,000 | +93.9% | 32,847 | +106.6% | 0.01% | +100.0% |
Q2 2022 | $560,000 | -41.2% | 15,902 | -23.1% | 0.00% | -20.0% |
Q1 2022 | $952,000 | -24.3% | 20,691 | +9.1% | 0.01% | -16.7% |
Q4 2021 | $1,257,000 | +29.5% | 18,965 | +21.9% | 0.01% | +20.0% |
Q3 2021 | $971,000 | -8.5% | 15,559 | +21.5% | 0.01% | -16.7% |
Q2 2021 | $1,061,000 | +46.7% | 12,807 | +17.5% | 0.01% | +50.0% |
Q1 2021 | $723,000 | +5.7% | 10,896 | +22.2% | 0.00% | 0.0% |
Q4 2020 | $684,000 | +183.8% | 8,914 | +59.4% | 0.00% | +100.0% |
Q3 2020 | $241,000 | +11.6% | 5,593 | -64.7% | 0.00% | +100.0% |
Q2 2018 | $216,000 | +390.9% | 15,849 | +93.1% | 0.00% | – |
Q2 2016 | $44,000 | – | 8,206 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |